Achaogen Inc (AKAO) Receives Average Rating of “Hold” from Brokerages

Achaogen Inc (NASDAQ:AKAO) has been given an average rating of “Hold” by the fourteen brokerages that are currently covering the company, MarketBeat reports. Two research analysts have rated the stock with a sell recommendation, four have assigned a hold recommendation and eight have given a buy recommendation to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $16.76.

A number of research analysts have recently issued reports on AKAO shares. Wedbush decreased their target price on Achaogen from $21.00 to $20.00 and set an “outperform” rating on the stock in a research report on Wednesday, June 27th. BidaskClub lowered Achaogen from a “hold” rating to a “sell” rating in a research report on Thursday, June 28th. increased their target price on Achaogen to $2.54 and gave the company a “sell” rating in a research report on Tuesday, July 3rd. ValuEngine lowered Achaogen from a “hold” rating to a “sell” rating in a research report on Tuesday, July 10th. Finally, Zacks Investment Research lowered Achaogen from a “hold” rating to a “sell” rating in a research report on Wednesday, July 25th.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Granahan Investment Management Inc. MA acquired a new position in Achaogen in the 2nd quarter valued at $1,220,000. Bank of America Corp DE raised its stake in Achaogen by 274.7% in the 2nd quarter. Bank of America Corp DE now owns 198,204 shares of the biopharmaceutical company’s stock valued at $1,717,000 after purchasing an additional 145,305 shares during the last quarter. Teton Advisors Inc. raised its stake in Achaogen by 324.2% in the 2nd quarter. Teton Advisors Inc. now owns 140,000 shares of the biopharmaceutical company’s stock valued at $1,212,000 after purchasing an additional 107,000 shares during the last quarter. Gamco Investors INC. ET AL raised its stake in Achaogen by 43.1% in the 2nd quarter. Gamco Investors INC. ET AL now owns 94,700 shares of the biopharmaceutical company’s stock valued at $820,000 after purchasing an additional 28,500 shares during the last quarter. Finally, Gabelli Funds LLC raised its stake in Achaogen by 18.6% in the 2nd quarter. Gabelli Funds LLC now owns 206,400 shares of the biopharmaceutical company’s stock valued at $1,787,000 after purchasing an additional 32,400 shares during the last quarter. 60.61% of the stock is owned by hedge funds and other institutional investors.

Achaogen stock traded up $0.08 during mid-day trading on Friday, hitting $4.01. The company had a trading volume of 21,766 shares, compared to its average volume of 903,591. The company has a current ratio of 3.79, a quick ratio of 3.79 and a debt-to-equity ratio of 0.42. Achaogen has a 12-month low of $3.31 and a 12-month high of $15.00. The firm has a market cap of $186.26 million, a PE ratio of -1.26 and a beta of 0.70.

Achaogen (NASDAQ:AKAO) last announced its earnings results on Monday, August 6th. The biopharmaceutical company reported ($1.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.92) by ($0.19). Achaogen had a negative net margin of 2,286.21% and a negative return on equity of 146.50%. The business had revenue of $2.56 million for the quarter, compared to analysts’ expectations of $1.49 million. On average, equities research analysts forecast that Achaogen will post -3.78 EPS for the current year.

About Achaogen

Achaogen, Inc, a late-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections in the United States. The company is principally developing plazomicin for the treatment of serious bacterial infections, including urinary tract infections, blood stream infections, and other infections due to MDR enterobacteriaceae comprising carbapenem-resistant enterobacteriaceae.

See Also: Asset Allocation

Analyst Recommendations for Achaogen (NASDAQ:AKAO)

Receive News & Ratings for Achaogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achaogen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply